OxRML/AgentSLR huggingface dataset:
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 5 / 43 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Central-West
Setting: Hospital based, Unspecified
Sample size: 43
Study period: Jan 2017 - Apr 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 12.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 15.4
Numerator/denominator: 60 / 496 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Other
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Adamawa, Bauchi, and Borno states
Setting: Population based, Both urban and rural areas
Sample size: 496
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 85 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 170 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Population based, Unspecified
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 13.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 10.8 - 22.2
Numerator/denominator: 65 / 496 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Other
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Adamawa, Bauchi, and Borno states
Setting: Population based, Both urban and rural areas
Sample size: 496
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 15.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 31 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Adamawa state
Setting: Population based, Both urban and rural areas
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 14.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 29 / 96 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Population based, Both urban and rural areas
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 6 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Adamawa state
Setting: Population based, Both urban and rural areas
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 36.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 35 / 96 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Bauchi state
Setting: Population based, Both urban and rural areas
Sample size: 96
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 12 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 24 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Population based, Both urban and rural areas
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 9.4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 16 / 170 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Population based, Unspecified
Sample size: 200
Study period: Apr 2018 - Aug 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 59 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 50.7 - 66.7 (95% CI)
Numerator/denominator: 85 / 144 (method: )
Population: Other, sex: Unspecified, ages  to 
Country: Brazil
Location: University Hospital Professor Edgard Santos (UHPES) in Salvador de Bahia
Setting: Hospital based, Unspecified
Sample size: 144
Study period: Feb 2016 - May 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 38.6 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 31.3 - 47 (95% CI)
Numerator/denominator: 56 / 144 (method: )
Population: Other, sex: Unspecified, ages  to 
Country: Brazil
Location: University Hospital Professor Edgard Santos (UHPES) in Salvador de Bahia
Setting: Hospital based, Unspecified
Sample size: 144
Study period: Aug 2017 - Feb 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 30 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 24 / 85 (method: )
Population: Other, sex: Unspecified, ages  to 
Country: Brazil
Location: University Hospital Professor Edgard Santos (UHPES) in Salvador de Bahia
Setting: Hospital based, Unspecified
Sample size: 85
Study period: Feb 2016 - May 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 23.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 5 / 21 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Unspecified
Sample size: 21
Study period: 18 Jan 2016 - 16 Dec 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 80.9 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 17 / 21 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Unspecified
Sample size: 21
Study period: 18 Jan 2016 - 16 Dec 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 4.2 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 4 / 95 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Unspecified
Sample size: 95
Study period: 18 Jan 2016 - 16 Dec 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 74.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 71 / 95 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Unspecified
Sample size: 95
Study period: 18 Jan 2016 - 16 Dec 2016
Parameter: Seroprevalence - HAI/HI (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 27.7 - 36.6
Statistical approach: Observed sample statistic
Disaggregated by: Age
Population: Other, sex: , ages  to 
Country: Brazil
Location: Manaus (Amazonas state)
Setting: Other, 
Sample size: 298
Study period: Jan 2014 - Dec 2015
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 16.7 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 5 / 30 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 30
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 21.4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 104 / 487 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 497
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 16 Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 95 / 594 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 594
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 57.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 4 / 7 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 7
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 77.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 34 / 44 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 44
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 86 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 38 / 44 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Italy
Setting: Travel based, Unspecified
Sample size: 44
Study period: Nov 2015 - Nov 2022
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 30 / 160 (method: )
Disaggregated by: Age, Sex
Population: , sex: Both, ages 3 to 
Country: Ghana
Location: Greater Accra Regional Hospital
Setting: Hospital based, Unspecified
Sample size: 160
Study period: Dec 2016 - Nov 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 3 / 160 (method: )
Disaggregated by: Age, Sex
Population: , sex: Both, ages 3 to 
Country: Ghana
Location: Greater Accra Regional Hospital
Setting: Hospital based, Unspecified
Sample size: 160
Study period: Dec 2016 - Nov 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0  ()
Exponent (base 10): 0
Numerator/denominator: 0 / 45 (method: )
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages 0 to 0
Country: Indonesia
Setting: Population based, Unspecified
Sample size: 45
Study period: Oct 2016 - Apr 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0  ()
Exponent (base 10): 0
Numerator/denominator: 0 / 113 (method: )
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages 0 to 0
Country: Indonesia
Setting: Population based, Unspecified
Sample size: 113
Study period: Oct 2016 - Apr 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 2  ()
Exponent (base 10): 0
Numerator/denominator: 1 / 46 (method: )
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages 0 to 0
Country: Indonesia
Setting: Population based, Unspecified
Sample size: 46
Study period: Oct 2016 - Apr 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 2  ()
Exponent (base 10): 0
Numerator/denominator: 2 / 110 (method: )
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages 0 to 0
Country: Indonesia
Setting: Population based, Unspecified
Sample size: 110
Study period: Oct 2016 - Apr 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 1.2 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 81 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Germany
Location: Germany travelling to Asia
Setting: Travel based, 
Sample size: 81
Study period: Jan 2017 - Jan 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1.2 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 81 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Germany
Location: Germany travelling to Asia
Setting: Travel based, 
Sample size: 81
Study period: Jan 2017 - Jan 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 40.54 Percentage (%) ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 15 / 37 (method: )
Seroprevalence adjustment: Naive
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Recife
Setting: Population based, 
Sample size: 262
Study period: Jan 2016 - Dec 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1.8 Percentage (%) ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 5 / 273 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Population: General population, sex: Both, ages  to 
Country: China
Location: Nanning City, Guanxi
Setting: Population based, 
Sample size: 273
Study period: Mar 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 9.5 Percentage (%) ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 26 / 273 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Population: General population, sex: Both, ages  to 
Country: China
Location: Nanning City, Guanxi
Setting: Population based, 
Sample size: 273
Study period: Mar 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 65.4 Percentage (%) ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 17 / 26 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Population: General population, sex: Both, ages  to 
Country: China
Location: Nanning City, Guanxi
Setting: Population based, 
Sample size: 273
Study period: Mar 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 3 Percentage (%) ()
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 63 / 2749 (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Rio de Janeiro
Setting: Population based, 
Sample size: 2749
Study period: Jul 2018 - Oct 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.2 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.01 - 1.1 (95% CI)
Population: Other, sex: , ages  to 
Country: United States
Location: Puerto Rico
Setting: Other, 
Sample size: 494
Study period: 1 Jan 2015 - 1 Jun 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 5.9 Percentage (%) ()
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 59 / 989 (method: Naive)
Seroprevalence adjustment: Naive
Population: Mixed groups, sex: Female, ages  to 
Country: Tanzania
Location: Buhigwe, Kalambo, Kilindi, Kinondoni, Kondoa, Kyela, Mvomero and Ukerewe districts
Setting: Population based, 
Sample size: 1818
Study period: Apr 2018 - Nov 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 7.5 Percentage (%) ()
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 62 / 829 (method: Naive)
Seroprevalence adjustment: Naive
Population: Mixed groups, sex: Male, ages  to 
Country: Tanzania
Location: Buhigwe, Kalambo, Kilindi, Kinondoni, Kondoa, Kyela, Mvomero and Ukerewe districts
Setting: Population based, 
Sample size: 1818
Study period: Apr 2018 - Nov 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 6.1 - 7.6
Case definition: Unspecified
Numerator/denominator:  / 1818 (method: Naive)
Seroprevalence adjustment: Naive
Disaggregated by: Age
Population: Mixed groups, sex: Both, ages  to 
Country: Tanzania
Location: Buhigwe, Kalambo, Kilindi, Kinondoni, Kondoa, Kyela, Mvomero and Ukerewe districts
Setting: Population based, 
Sample size: 1818
Study period: Apr 2018 - Nov 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 6.8 Percentage (%) ()
Exponent (base 10): 0
Population: Mixed groups, sex: Both, ages  to 
Country: Tanzania
Location: Buhigwe, Kalambo, Kilindi, Kinondoni, Kondoa, Kyela, Mvomero and Ukerewe districts
Setting: Population based, 
Sample size: 1818
Study period: Apr 2018 - Nov 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 84.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 39 / 48 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Community based, Urban area
Sample size: 48
Study period: Jan 2015 - Dec 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 0 - 3.4
Statistical approach: Observed sample statistic
Disaggregated by: Age
Population: Pregnant women, sex: Both, ages  to 
Country: Brazil
Location: Diamantina
Setting: Population based, 
Sample size: 135
Study period: 2018 - 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 4.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 3.6 - 6.2
Case definition: Lab confirmed
Numerator/denominator:  / 1036 (method: )
Seroprevalence adjustment: Unspecified
Statistical approach: Unspecified
Disaggregated by: Age, Region, Sex, Time
Population: Other, sex: Both, ages  to 
Country: Madagascar
Setting: Hospital based, Both urban and rural areas
Sample size: 1036
Study period: Jan 2018 - Jun 2021
Parameter: Attack rate (Attack rate)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 560 / 1110 (method: Naive)
Population: Persons under investigation, sex: Both, ages 2 to 14
Country: Nicaragua
Location: Managua
Setting: Hospital based, 
Sample size: 1110
Study period: Jan 2016 - Feb 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 2.8 Percentage (%) ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator:  /  (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Thailand
Setting: Population based, 
Sample size: 254
Study period: Dec 2017 - Feb 2020
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 33.2 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 237 / 713 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 1 to 16
Country: United States
Location: Ponce, Puerto Rico
Setting: Community based, Unspecified
Sample size: 713
Study period: 2018 - 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 12.5 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator:  / 713 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 1 to 16
Country: United States
Location: Ponce, Puerto Rico
Setting: Community based, Urban area
Sample size: 713
Study period: 2018 - 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 29.1 - 55
Disaggregated by: Age, Sex, Time
Population: General population, sex: , ages  to 
Country: Gabon
Location: Lambarene
Setting: Population based, 
Sample size: 462
Study period: Nov 2014 - Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 72.3 Percentage (%) ()
Exponent (base 10): 0
Case definition: Suspected
Numerator/denominator: 73 / 101 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Population based, 
Sample size: 101
Study period: Jan 2016 - Dec 2016
Parameter: Severity - case fatality rate (CFR) (Severity)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Numerator/denominator: 2 / 87 (method: )
Population: Persons under investigation, sex: , ages  to 
Country: France
Location: Guadeloupe, Martinique
Setting: Hospital based, 
Study period: 6 Jan 2016 - 13 Sep NA
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 69.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 53 / 76 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Male, ages 23 to 62
Country: Papua New Guinea
Location: Manus Island
Setting: Other, 
Sample size: 76
Study period: Apr 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 66 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 87 / 132 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 20 to 59
Country: Papua New Guinea
Location: Wewak
Setting: Other, 
Sample size: 132
Study period: Apr 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 9 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 7 / 76 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Male, ages 23 to 62
Country: Papua New Guinea
Location: Manus Island
Setting: Other, 
Sample size: 76
Study period: Apr 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 9.1 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 12 / 132 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 20 to 59
Country: Papua New Guinea
Location: Wewak
Setting: Other, 
Sample size: 132
Study period: Apr 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 63.2 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 48 / 55 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Male, ages 23 to 62
Country: Papua New Guinea
Location: Manus Island
Setting: Other, 
Sample size: 76
Study period: Apr 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 65.9 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 87 / 93 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 20 to 59
Country: Papua New Guinea
Location: Wewak
Setting: Other, 
Sample size: 132
Study period: Apr 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Bounds: 2.4 - 27.1
Case definition: Clinically diagnosed/symptomatic;Suspected
Numerator/denominator: 286 / 768 (method: )
Seroprevalence adjustment: Naive
Disaggregated by: Age
Population: Persons under investigation, sex: Both, ages  to 
Country: Mexico
Location: Merida
Setting: Hospital based, 
Sample size: 768
Study period: 2020
Parameter: Mutations - mutation rate (Mutations)
Value: 0.3695 Mutations/site/generation (mu) (Mean)
Exponent (base 10): 0
Uncertainty: 0.2976 - 0.4482 (HPDI 95%)
Statistical approach: Estimated model parameter
Genome site: NS5; 1st codon
Population: Persons under investigation, sex: , ages  to 
Country: Multi-country: Americas (n = 13), Asia (n = 3), Africa (n = 2), Oceania (n = 1)
Setting: Population based, 
Sample size: 108
Study period: 1947 - Oct 2017
Parameter: Mutations - mutation rate (Mutations)
Value: 0.1596 Mutations/site/generation (mu) (Mean)
Exponent (base 10): 0
Uncertainty: 0.1133 - 0.2111 (HPDI 95%)
Statistical approach: Estimated model parameter
Genome site: NS5; 2nd codon
Population: Persons under investigation, sex: , ages  to 
Country: Multi-country: Americas (n = 13), Asia (n = 3), Africa (n = 2), Oceania (n = 1)
Setting: Population based, 
Sample size: 108
Study period: 1947 - Oct 2017